Nexstim Oyj

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: FI4000506811
EUR
14.50
0.00 (0.00%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

EUR 105 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.66

stock-summary
Return on Equity

-8.90%

stock-summary
Price to Book

32.90

Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
10.69%
0%
10.69%
6 Months
73.44%
0%
73.44%
1 Year
134.63%
0%
134.63%
2 Years
504.17%
0%
504.17%
3 Years
245.24%
0%
245.24%
4 Years
225.84%
0%
225.84%
5 Years
211.78%
0%
211.78%

Nexstim Oyj for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
21.82%
EBIT Growth (5y)
14.89%
EBIT to Interest (avg)
-0.77
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.41
Sales to Capital Employed (avg)
1.02
Tax Ratio
0.55%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
5.39%
ROE (avg)
6.42%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
33.11
EV to EBIT
107.39
EV to EBITDA
107.39
EV to Capital Employed
20.30
EV to Sales
10.67
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
0.17%
ROE (Latest)
-8.90%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Nexstim Oyj"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2023 is -24.21% vs 48.44% in Dec 2022",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2023 is -200.00% vs 262.50% in Dec 2022",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'23",
        "Dec'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "7.20",
          "val2": "9.50",
          "chgp": "-24.21%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.00",
          "val2": "1.10",
          "chgp": "-190.91%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.30",
          "val2": "1.30",
          "chgp": "-200.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-166.20%",
          "val2": "84.60%",
          "chgp": "-25.08%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Annual Results Snapshot (Consolidated) - Dec'23stock-summary
Dec'23
Dec'22
Change(%)
Net Sales
7.20
9.50
-24.21%
Operating Profit (PBDIT) excl Other Income
-1.00
1.10
-190.91%
Interest
0.10
0.10
Exceptional Items
-0.00
0.00
Consolidate Net Profit
-1.30
1.30
-200.00%
Operating Profit Margin (Excl OI)
-166.20%
84.60%
-25.08%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2023 is -24.21% vs 48.44% in Dec 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2023 is -200.00% vs 262.50% in Dec 2022

stock-summaryCompany CV
About Nexstim Oyj stock-summary
stock-summary
Nexstim Oyj
Pharmaceuticals & Biotechnology
Nexstim Oyj is a Finland-based medical technology company. It is focused on improving rehabilitation for stroke patients through the use of noninvasive brain stimulation. Its offering comprises: a diagnostic tool for brain surgery planning, Navigated Brain Stimulation (NBS) System, which comprises navigated transcranial magnetic stimulation (nTMS) device for presurgical mapping (PSM) of the motor and speech cortices; and a device for stroke therapy called Navigated Brain Therapy (NBT) System, which focuses stimulation on targeted locations in the brain in order to enhance rehabilitation process. The NBT System targets upper limb motor disability and is under Phase III pivotal clinical trial study at rehabilitation sites in the United States. The Company’s systems are used in over 100 facilities in research, therapy and neurosurgical planning purposes. Nexstim Oyj has two subsidiaries: Nexstim Inc and Nexstim Germany GmbH.
Company Coordinates stock-summary
Company Details
Elimaenkatu 9 B , HELSINKI None : 00510
stock-summary
Tel: 358 9 272717044 20 37095700
stock-summary
Registrar Details